| Trial ID: | L1782 |
| Source ID: | NCT05667220
|
| Associated Drug: |
Sitagliptin
|
| Title: |
Sitagliptin in Combination With Beidougen Capsule for Type 2 Diabetes
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Sitagliptin|DRUG: Sitagliptin combined with Beidougen capsule
|
| Outcome Measures: |
Primary: Fasting blood glucose change, Fasting blood glucose (FBG) levels (mmol/L) were analyzed by an autoanalyzer (Hitachi 747, Roche Diagnostics, Germany) at the Central Chemistry Laboratory of Beijing Chaoyang Hospital affiliated with Capital Medical University., Changes in fasting blood glucose from baseline to 1 week treatment | Secondary: Serum GLP-1 change, The serum active GLP-1 contents were measured using an active GLP-1 assay kit (EZGLPHS-35K, Millipore) according to the specification., Changes in serum GLP-1 from baseline to 1 week treatment|Fecal DPP4 activity change, For measurement of fecal DPP4 activity, 60 mg feces were homogenized in RIPA lysis buffer (with final concentration at 1 mg/mL) was added to 50 mM sodium phosphate buffer (pH = 7.4, OD600 = 0.5), and the reaction was started by the addition of 250 μM H-A-pNA. After incubation for 30 min at 37 °C, the absorbance was measured at 405 nm., Changes in fecal DPP4 activity from baseline to 1 week treatment
|
| Sponsor/Collaborators: |
Sponsor: Beijing Chao Yang Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
20
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2022-12-01
|
| Completion Date: |
2023-12-31
|
| Results First Posted: |
|
| Last Update Posted: |
2023-01-03
|
| Locations: |
Beijing Chao-yang Hospital, Capital Medical University, Beijing, Beijing, 100020, China
|
| URL: |
https://clinicaltrials.gov/show/NCT05667220
|
